Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Celltrion, Inc.    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
294000 296500 301000 301500 330000 Last
1008373 534421 980581 845718 10726000 Volume
+1.03% +0.85% +1.52% +0.17% +9.45% Change
Financials
Sales 2020 1 871 B 1,69 B 1,69 B
Net income 2020 583 B 0,53 B 0,53 B
Net cash position 2020 498 B 0,45 B 0,45 B
P/E ratio 2020 75,9x
Yield 2020 0,00%
Sales 2021 2 155 B 1,95 B 1,95 B
Net income 2021 702 B 0,63 B 0,63 B
Net cash position 2021 912 B 0,82 B 0,82 B
P/E ratio 2021 65,1x
Yield 2021 0,00%
Capitalization 44 130 B 39 870 M 39 893 M
EV / Sales 2020 23 580x
EV / Sales 2021 20 478x
Nbr of Employees 908
Free-Float 68,3%
More Financials
Company
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical... 
More about the company
Notations Surperformance© of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about CELLTRION, INC.
11/06CELLTRION, INC. : quaterly earnings release
11/05Celltrion's COVID-19 antibody drug cut recovery time-early study
RE
11/05CELLTRION HEALTHCARE : says Phase 1 trial shows COVID-19 antibody drug 'well-tol..
RE
11/04S.Korea shares extend gains as investors eye tight U.S. election race
RE
11/03S.Korea stocks gain most in nearly 5 months on strong global data
RE
10/27S.Korea begins preliminary review of AstraZeneca's COVID-19 vaccine candidate
RE
10/26S.Korea shares dip as surging global coronavirus cases dent sentiment
RE
10/26South Korea pharma Celltrion's COVID test gets U.S. emergency use authorisati..
RE
10/25S.Korea pharma Celltrion's COVID test gets U.S. emergency use authorisation
RE
10/14CELLTRION : COVID-19 antibody treatment to enter Phase III trial
AQ
10/12S.Korea shares extend rally to eighth day on U.S. stimulus hopes
RE
10/12CELLTRION : South Korea's Celltrion gets approval for Phase 3 trials of COVID-19..
RE
09/28Investors swamp IPO for K-Pop band BTS management label, prices at top of ran..
RE
09/28S.Korea shares jump most in two weeks on falling virus cases, upbeat China da..
RE
09/27Investors swamp IPO for K-Pop band BTS management label, prices at top of ran..
RE
More news
News in other languages on CELLTRION, INC.
11/06CELLTRION, INC. : publication des résultats trimestriels
11/06CELLTRION, INC. : Veröffentlichung des Quartalsergebnisses
08/10CELLTRION, INC. : publication des résultats semestriels
08/10CELLTRION, INC. : Veröffentlichung des Halbjahresergebnisses
06/11Tokyo démarre en forte baisse, inquiétudes sur les Etats-Unis
More news
Analyst Recommendations on CELLTRION, INC.
More recommendations
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | A068270 | KR7068270008 | MarketScreener
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 313 555,56 KRW
Last Close Price 330 000,00 KRW
Spread / Highest target 36,4%
Spread / Average Target -4,98%
Spread / Lowest Target -63,0%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Chief Executive Officer & Director
Jung-Jin Seo Chairman
Ho-Seop Lee Finance Director
Dong-Il Kim Independent Director
Joseph Lee Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.82.32%36 284
LONZA GROUP AG56.17%44 950
MODERNA, INC.403.89%39 001
IQVIA HOLDINGS INC.11.32%32 977
SEAGEN INC.44.80%29 684
IMMUNOMEDICS, INC.315.22%20 324